Axsome Therapeutics recently reported that the FDA accepted its supplemental application and granted priority review for AXS-05 to treat agitation in Alzheimer’s disease, while also confirming that ...
The sNDA for AXS-05 for Alzheimer disease agitation includes findings from four phase 3 trials showing improved behaviors and delayed relapse.
Axsome Therapeutics (AXSM) has quickly moved onto investors' radar after the FDA accepted a priority review for AXS-05 in Alzheimer’s agitation and signaled support for an NDA filing for narcolepsy ...
Zacks Investment Research on MSN
AXSM up on FDA priority review to AXS-05 sNDA in Alzheimer's agitation
Shares of Axsome Therapeutics AXSM were up 22.8% on Dec. 31, after it announced that the FDA had accepted the supplemental ...
Zacks Investment Research on MSN
AXS stock moves above 50 & 200-day SMA: Buy, sell or stay invested?
Shares of Axis Capital Holdings AXS have gained momentum. The stock is trading above its 50 and 200-day simple moving average ...
FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026NEW YORK, (GLOBE NEWSWIRE) -- ...
AXIS Capital Holdings Limited, through its subsidiaries, provides various specialty insurance and reinsurance products in Bermuda, the United States, and internationally. It operates through two ...
New Drug Application (NDA) submission on track for January 2026NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: ...
AXS, the global advanced ticketing and live event technology company, has announced two key leadership appointments as part of its continued technology transformation and global growth. Nikhil Bobde ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback